Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S.

The Society of Interventional Radiology (SIR) announced that the CAPTAIN randomized clinical trial found that men with ...

A recent randomized clinical trial has found that men with localized, intermediate-risk prostate cancer recovered faster and ...

Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and ...

MRI-guided transurethral ultrasound ablation associated with less blood loss, shorter stays, and less pain than robotic prostatectomy.

Francis Medical, Inc., a privately held medical device company based in Maple Grove, Minn., today announced that Aaron ...

Industry trade associations made the case for revisions to draft guidance on clinical testing recommendations for prostate tissue ablation devices in comments earlier this month. The Medical Imaging & ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...

High-intensity focused ultrasound (HIFU) is a noninvasive way to destroy tissue or stop it from working. It was approved by the U.S. Food and Drug Administration for prostate ablation in 2015, but the ...

The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued draft guidance Tuesday to support clinical testing of high-intensity ultrasound systems for ...